Research Center of Biotechnology, School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009, China; Department of Pharmacology, School of Basic Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211166, China.
Division of Pharmacy, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, 210009, China.
Toxicology. 2019 Jun 15;422:60-68. doi: 10.1016/j.tox.2019.04.008. Epub 2019 Apr 18.
Insulin is a major therapy for diabetes, and therefore, its role and mechanisms in the regulation of drug-metabolizing enzymes (DMEs), is of clinical importance to facilitate the rational drug use. Carboxylesterases are regarded as one of the major determinants of the metabolism and disposition of various substrates through their actions in the liver and intestine, alterations in the activity of CESs enzymes are often important causes of drug interactions. Therefore, investigation on the mechanism of CESs regulation is significantly important. In this study, we demonstrated that insulin markedly down-regulated CESs expression and suppressed the hydrolytic activity of CESs in an Akt-dependent manner. Moreover, overexpression of PXR abrogated the decrease of CES1 and CES2 expression induced by insulin in HepG2 cells, suggesting PXR was involved in insulin-induced reduction of CESs. Mechanistically, luciferase reporter assay showed that PXR increased the transcriptional activity of CES1 and CES2 gene promoter, and chromatin immunoprecipitation assay verified that PXR bound to the site (-244 to -234) in CES1 gene promoter region and bound to the site (-814 to -804 and -794 to -784) in CES2 gene promoter region for the first time. In summary, our data indicate that down-regulation of PXR mediates insulin-induced suppression of CESs. Accordingly, insulin may impact the therapeutic effects of carboxylesterases substrate drugs and also inhibit expression of other genes targeted by PXR, thus inducing a wide range of potential drug-drug interactions (DDIs) during the treatment of diabetes.
胰岛素是糖尿病的主要治疗药物,因此,其在调节药物代谢酶(DMEs)中的作用和机制对促进合理用药具有重要的临床意义。羧酸酯酶被认为是通过在肝脏和肠道中的作用调节各种底物代谢和分布的主要决定因素之一,CESs 酶活性的改变通常是药物相互作用的重要原因。因此,研究 CESs 调节的机制具有重要意义。在本研究中,我们证明胰岛素通过 Akt 依赖性途径显著下调 CESs 的表达并抑制 CESs 的水解活性。此外,PXR 的过表达消除了胰岛素在 HepG2 细胞中诱导的 CES1 和 CES2 表达下降,表明 PXR 参与了胰岛素诱导的 CESs 减少。机制上,荧光素酶报告基因 assay 表明 PXR 增加了 CES1 和 CES2 基因启动子的转录活性,染色质免疫沉淀 assay 首次验证了 PXR 结合到 CES1 基因启动子区域的-244 至-234 位和 CES2 基因启动子区域的-814 至-804 位和-794 至-784 位。综上所述,我们的数据表明,PXR 的下调介导了胰岛素诱导的 CESs 抑制。因此,胰岛素可能会影响羧酸酯酶底物药物的治疗效果,并抑制 PXR 靶向的其他基因的表达,从而在治疗糖尿病期间引发广泛的潜在药物-药物相互作用(DDIs)。